A biosimilar of Rituxan, a novel cancer drug & more: 5 latest FDA approvals

Here are five drugs or medical devices approved by the FDA since Nov. 23:

1. The first biosimilar of Rituxan, called Truxima, was approved for the treatment of adult patients with non-Hodgkin lymphoma.

2. Xospata, which are tablets, treat adult patients who have acute myeloid leukemia with a certain genetic mutation or who were in remission and relapsed.

3. The FDA approved Firdapse, the first treatment for Lambert-Eaton myasthenic syndrome,  a rare autoimmune disorder that affects the connection between nerves, causing weakness in affected patients.

4. Vitrakvi is an oncology drug that treats cancers that have a specific genetic feature, also known as a biomarker. It does not target a specific type of tumor like many cancer treatments.

5. ATCPen, a single-dose prefilled autoinjector of tocilizumab, for the treatment of moderate to severe rheumatoid arthritis.

More articles on supply chain:
What's next? 5 predictions for the healthcare supply chain in 2019
Cleveland Clinic leads list of 25 top healthcare supply chains for 2018
Sales reps may get the boot from hospital ORs

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months